<DOC>
	<DOCNO>NCT00444223</DOCNO>
	<brief_summary>RATIONALE : Fluorine F 18 FEQA may effective radioactive drug use positron emission tomography ( PET ) scan . PURPOSE : This clinical trial study use fluorine F 18 FEQA patient stage III stage IV non-small cell lung cancer healthy participant .</brief_summary>
	<brief_title>Fluorine F 18 FEQA Patients With Stage III Stage IV Non-Small Cell Lung Cancer Healthy Participants</brief_title>
	<detailed_description>OBJECTIVES : - Determine biodistribution fluorine F 18 FEQA patient stage III IV non-small cell lung cancer ( NSCLC ) healthy participant . - Determine whether fluorine F 18 FEQA use image agent positron emission tomography patient stage III IV NSCLC . OUTLINE : This pilot study . Patients healthy participant receive fluorine F 18 FEQA IV undergo whole-body dynamic scan comprise positron emission tomography . Blood collect imaging measure radioactivity . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<criteria>Must meet 1 follow criterion : Diagnosis nonsmall cell lung cancer CT scan , bone scan , biopsy Stage III IV disease Clinically assess Healthy participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>